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Abstract Insulin resistance is a hallmark of type 2 diabetes
mellitus and is associated with a metabolic and cardiovascular
cluster of disorders (dyslipidaemia, hypertension, obesity
[especiallyvisceral],glucoseintolerance,endothelialdysfunc-
tion), each of which is an independent risk factor for
cardiovascular disease (CVD). Multiple prospective studies
have documented an association between insulin resistance
and accelerated CVD in patients with type 2 diabetes, as well
asinnon-diabeticindividuals.Themolecularcausesofinsulin
resistance, i.e. impaired insulin signalling through the
phosphoinositol-3 kinase pathway with intact signalling
through the mitogen-activated protein kinase pathway, are
responsible for the impairment in insulin-stimulated glucose
metabolism and contribute to the accelerated rate of CVD in
type 2 diabetes patients. The current epidemic of diabetes is
being driven by the obesity epidemic, which represents a state
of tissue fat overload. Accumulation of toxic lipid metabolites
(fatty acyl CoA, diacylglycerol, ceramide) in muscle, liver,
adipocytes, beta cells and arterial tissues contributes to insulin
resistance, beta cell dysfunction and accelerated atherosclero-
sis, respectively, in type 2 diabetes. Treatment with thiazoli-
dinediones mobilises fat out of tissues, leading to enhanced
insulin sensitivity, improved beta cell function and decreased
atherogenesis. Insulin resistance and lipotoxicity represent the
missinglinks(beyondtheclassicalcardiovascularriskfactors)
thathelpexplaintheacceleratedrateofCVDintype2diabetic
patients.
Keywords Cardiovasculardisease.Endothelial
dysfunction.Insulinresistance.Insulinsignalling.
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Abbreviations
ACCORD Action to Control Cardiovascular Risk in
Diabetes
ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation
CVD Cardiovascular disease
ERK Extracellular regulated kinase
HOMA-IR HOMA of insulin resistance
IkB Inhibitor kβ
MAP Mitogen-activated protein
NF-kB Nuclear factor kβ
PDGF Platelet-derived growth factor
PGC-1 PPARγ coactivator-1
PI Phosphoinositol
PKC Protein kinase C
PPAR Peroxisome proliferator-activated receptor
VADT Veterans Administration Diabetes Trial
VSMC Vascular smooth muscle cells
Introduction
Type 2 diabetes mellitus is a complex metabolic disorder
complicated by microvascular and macrovascular disease
[1]. Hyperglycaemia is the major risk factor for microvas-
cular complications [2, 3] and reduction in HbA1c decreases
the incidence of retinopathy, nephropathy and neuropathy
[2, 3]. For every 1% decrement in HbA1c, the incidence of
microvascular complications is reduced by ∼25% to 35%.
Although microvascular complications are a major cause of
morbidity,macrovascular complications representthe primary
cause ofmortality withheart attacks andstrokeaccountingfor
around 80% of all deaths [4]. In type 2 diabetic patients
without prior history of myocardial infarction, the 7-year
incidence of myocardial infarction is equal to or greater than
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uals with prior myocardial infarction [5]. In diabetic patients
with a previous heart attack, the 7-year incidence of
subsequent myocardial infarction is more than double
(45%) that of non-diabetic individuals [5]. Similarly, the
recurrence rate of major atherosclerotic complications in type
2 diabetic patients with a prior cardiovascular event is very
high, around 6% per year [6]. These results document that
diabetes is a cardiovascular equivalent.
Hyperglycaemia and cardiovascular disease
Given the above observations and the negative results of
the ACCORD [7], ADVANCE [8] and VADT [9] studies,
in which intensified glycaemic control failed to reduce
macrovascular complications, it is reasonable to ask what
role hyperglycaemia plays in the development of cardio-
vascular disease (CVD). Epidemiological analysis of the
UKPDS [3] demonstrated that rising HbA1c was associated
with increased risk of myocardial infarction and stroke.
However, the increased hazard ratio was modest and
r e d u c t i o ni nH b A 1c following insulin or sulfonylurea
therapy did not significantly decrease myocardial infarc-
tions or strokes [10], although long-term follow up did
demonstrate a significant reduction in atherosclerotic
cardiovascular events [11]. These results suggest a ‘mem-
ory’ effect of improved glycaemic control, reminiscent of
the Diabetes Control and Complications Trial in type 1
diabetic patients [12].
The negative results of the ACCORD, ADVANCE
and VADT [7–9] studies have also led to questioning of
the notion that improved glycaemic control prevents
macrovascular complications in type 2 diabetic patients,
especially in those with long-standing diabetes. What, for
example, could explain the failure to observe a reduction
in macrovascular events in these studies (see textbox:
Insulin and atherosclerosis)?
First, the underlying hypothesis is not based on sound
pathophysiological evidence. Hyperglycaemia is a weak risk
factor for CVD compared with other well established risk
factors, e.g. dyslipidaemia and hypertension; moreover, most
patients in the above studies were being treated with lipid-
lowering medications, antihypertensive drugs and anti-
inflammatory agents [7–9]. Second, participants had long-
standing diabetes with a prior cardiovascular event or
multiple risk factors for CVD. Third, insulin may be the
wrong drug for prevention of CVD. Insulin is associated with
weight gain [13, 14] and weight gain (obesity) is a major risk
factor for CVD [15, 16]. Moreover, even small increments in
plasma insulin cause severe insulin resistance [17, 18], which
is also a risk factor for CVD. Fourth, the study population,
although large in the ACCORD and ADVANCE studies, was
inadequate, given the low annual incidence of cardiovascular
complications (∼2% per year), to demonstrate a beneficial
effect of improved glycaemic control.
Insulin and atherosclerosis
Many in vivo and in vitro studies have demonstrated that
insulin, especially at high doses, can promote atherogenesis
[19–21] (see textbox: Insulin and atherosclerosis). Insulin
promotes de novo lipogenesis and augments hepatic VLDL
synthesis [22, 23] via its stimulation of sterol regulatory-
element-binding protein-1c and its inhibition of acetyl-CoA
carboxylase [24]. In cultured arterial smooth muscle cells,
insulin augmented LDL-cholesterol transport [25]. Insulin
is a potent growth factor, augments collagen synthesis [26,
27], stimulates arterial smooth muscle cell proliferation [28,
29] and turns on multiple genes involved in inflammation
[27].
In vivo studies in dogs [30], rabbits [31] and chickens
[32] provide further evidence that insulin promotes athero-
genesis. Non-diabetic chickens fed a high-cholesterol diet
develop severe atherosclerosis, which regresses when
switched to low-cholesterol diet [32]. Insulin administration
when the low-cholesterol diet was instituted prevented
regression of coronary atherosclerosis. Alloxan-induced
diabetic rabbits fed a high-cholesterol diet developed
marked hypercholesterolaemia, but their aorta remained
free of atherosclerotic plaque [31]. If rabbits are treated
with insulin, severe atherosclerosis develops. Dogs receiv-
ing a low-dose insulin infusion into a hindlimb artery (to
cause local, physiological hyperinsulinaemia) developed
severe femoral atherosclerosis, whereas all other arteries
remained free of atherosclerotic plaque [30]. Rats chroni-
cally (7–10 days) infused with insulin while maintaining
euglycaemia became markedly resistant to the stimulation
of glucose uptake and suppression of plasma NEFA by
insulin [23], and became hypertensive [33].
Insulin and atherosclerosis 
Insulin: 
￿ enhances VLDL synthesis and may reduce
HDL-cholesterol levels
￿ increases cholesterol transport into arteriolar smooth
muscle cells 
￿ is a growth factor that: 
- augments collagen synthesis  
- stimulates proliferation of arteriolar smooth muscle
 cells  
￿ promotes atherogenesis in animal models (rabbit,
 chicken, dog)  
￿ causes insulin resistance 
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In humans with normal glucose tolerance, insulin infusion to
raise fasting plasma insulin from 57 to 104 pmol/l for 3 days
produced severe insulin resistance [17, 18], a risk factor for
CVD (see subsequent discussion). Finally, insulin therapy is
invariably associated with weight gain [13, 14]. Most studies
designed to reduce HbA1c <7.0% have required large insulin
doses, failed to achieve the targeted HbA1c goal and resulted
in weight gain [13, 14]. The study of Henry et al. [13]i s
especially noteworthy. HbA1c was reduced from 7.7% to
5.1%, but this was associated with weight gain of 8.6 kg.
This is of major concern since the current diabetes epidemic
is being driven by obesity, a major risk factor for CVD [15,
16]. Weight gain promotes atherogenesis via multiple
mechanisms including dyslipidaemia and hypertension. Fat
deposition in the arterial wall promotes inflammation, which
directly accelerates atherogenesis [34–37]. Interestingly,
27.8% of individuals in the intensive treatment arm of the
ACCORD study gained >10 kg [7].
Insulin resistance (metabolic) syndrome
Much evidence indicates that insulin resistance per se and
associated components of the insulin resistance (metabolic)
syndrome (see textbox: Syndrome of insulin resistance)
[38–40] contribute to development of CVD. Studies from
our laboratory (Fig. 1)[ 1, 9, 41–44] and others [45, 46]
have demonstrated that lean type 2 diabetic and obese
normal glucose tolerant participants are resistant to insulin
and that their insulin resistance primarily affects the
glycogen synthetic pathway. Type 2 diabetes [4, 5] and
obesity [15, 16] are major cardiovascular risk factors. A
common thread linking all components of the insulin
resistance (metabolic) syndrome is the basic cellular/
molecular cause of insulin resistance [44], which not only
promotes inflammation and atherogenesis, but leads to and/
or aggravates other components of the syndrome, which
themselves are major CVD risk factors.
Hypertension is a central feature of the insulin
resistance syndrome. Many studies have demonstrated
that hypertensive individuals are resistant to insulin,
primarily involving the glycogen synthetic pathway
(Fig. 1)[ 47–51], and hypertension is a well established
risk factor for CVD.
Type 2 diabetic and obese individuals develop dyslipi-
daemia characterised by hypertriacylglycerolaemia, reduced
HDL-cholesterol, and small dense atherogenic LDL par-
ticles [39, 40, 52, 53], each of which is a major CVD risk
factor. We and others [51, 54–57] have shown that hyper-
triacylglycerolaemia, but not hypercholesterolaemia is
associated with insulin resistance primarily involving the
glycogen synthetic pathway (Fig. 1). The frequency of
hypercholesterolaemia is not increased in patients with type
2 diabetes mellitus [53]. However, if elevated, LDL-
cholesterol acts synergistically with other risk factors to
accelerate atherogenesis [58].
To examine the relationship between insulin resistance
and CVD, we compared normal glucose-tolerant individu-
als with diffuse coronary artery disease with normal
glucose-tolerant participants with clean coronary arteries
[59]. Individuals with coronary artery disease manifested
marked insulin resistance, primarily affecting the glycogen
synthetic pathway in skeletal muscle [59] (Fig. 1). Studies
by Reaven [40] and Paternostro et al. [60] have demon-
strated that non-diabetic individuals with established coro-
nary artery disease are resistant to insulin. Using positron
emission tomography, the myocardium of non-diabetic
individuals with coronary artery disease [61] and type 2
diabetic patients without coronary artery disease [62] has
been shown to be resistant to insulin.
In summary, each component of the ‘metabolic’syndrome
is characterised by insulin resistance involving the glycogen
syntheticpathway(Fig. 1). Insulin resistance is present at the
stage of impaired glucose tolerance [63, 64] and even before
any abnormality in glucose tolerance is observed [65]. Thus,
we prefer to refer to the metabolic and cardiovascular cluster
of factors that comprise the ‘metabolic’ syndrome as the
‘insulin resistance syndrome’ [20, 21, 66]. This focuses
clearly on a specific pathogenic aetiology, rather than on a
diffuse cluster of factors that may or may not be related to
the same underlying pathophysiology.
Insulin resistance and the insulin resistance syndrome
predict future cardiovascular disease
Multiple prospective studies have demonstrated that insulin
resistance predicts future CVD. In the San Antonio Heart
Study [67], insulin resistance was quantitated by HOMA of
insulin resistance (HOMA-IR) in 2,564 non-diabetic par-
ticipants who were followed for 8 years. Individuals in the
Syndrome of insulin resistance
￿   Obesity (especially visceral)
￿   Glucose intolerance (impaired glucose tolerance,
      impaired fasting glucose, type 2 diabetes mellitus)
￿   Hypertension 
￿   Dyslipidaemia (high triacylglycerol, low HDL,
      small dense LDL particles) 
￿   Endothelial dysfunction 
￿   Atherosclerotic CVD 
￿   Hyperinsulinaemia 
￿   Insulin resistance 
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2.5-fold increased incidence of CVD (Fig. 2a). After
adjustment for multiple cardiovascular risk factors, indi-
viduals in the highest quintile of insulin resistance still had
a twofold increased incidence of CVD. In 3,606 non-
diabetic participants followed for 6.9 years in the Botnia
Study [68] (Fig. 2b), the metabolic syndrome was associ-
ated with a threefold increased risk of CVD. Each
component of the metabolic syndrome, as well as insulin
resistance (HOMA-IR) itself, was associated with a 1.5- to
2-fold increased incidence of CVD (Fig. 2b). Similar
observations have been made in the Bruneck [69], Verona
Diabetes [70] and Insulin Resistance Atherosclerosis
studies [71]. A strong relationship between HOMA-IR and
carotid intimal media thickness has also been demonstrated
[72], as has an association between insulin resistance and
greater cardiovascular risk factor load [73].
The analysis by D’Agostino et al. of six prospective
studies further supports an independent role for insulin
resistance in CVD [74]. It found that, using the Framingham
Cardiovascular Risk Engine [75], only 69% of the observed
risk for CVD could be explained, leaving 31% unaccounted
for (Fig. 3a). Similarly, in the ARIC study [76] (Fig. 3b),
only ∼70% of the increase in carotid intimal media thickness
could be accounted for by dyslipidaemia, hypertension,
glucose intolerance and obesity. We hypothesise that this
unexplained risk can be attributed to insulin resistance.
Molecular causes of insulin resistance syndrome
Normal insulin signalling As shown in Fig. 4a, for insulin
to exert its biological effects, it must first bind to specific
cell surface receptors [77, 78]. This activates ‘second
messengers’, which initiate a phosphorylation–dephosphor-
ylation cascade that stimulates glucose transport (via
GLUT4), glucose phosphorylation (via hexokinase II),
glycogen synthase (which controls glycogen synthesis)
and both phosphofructokinase and pyruvate dehydrogenase
(which regulate glycolysis and glucose oxidation) [79].
In muscle, insulin binding to its receptor [77, 79] leads
to tyrosine phosphorylation of IRS-1, which mediates
insulin’s effect on glucose metabolism. In liver, IRS-2
phosphorylation mediates the actions of insulin. IRS-1
activates phosphatidylinositol (PI)-3 kinase [80], which
catalyses 3′ phosphorylation of PI, PI-4 phosphate and PI-
4,5 diphosphate, and augments glucose transport and
glycogen synthase [81–83]. Inhibitors of PI-3 kinase inhibit
glucose transport [82], hexokinase II [84] and glycogen
synthase [85].
Insulin signalling also plays a critical role in activating
nitric oxide synthase, which regulates nitric oxide pro-
duction [86–88]. Nitric oxide is a potent vasodilator and
anti-atherogenic agent [86]. Nitric oxide deficiency acti-
vates multiple pathways involved in atherogenesis [89, 90].
Fig. 2 a Association between insulin resistance (HOMA-IR) and 8-
year incidence of CVD in non-diabetic participants in the San Antonio
Heart Study before (black bars) and after (white bars) adjustment for
age, sex, blood pressure, plasma lipids, smoking, exercise and waist
circumference. Events, n=187, participants, n=2,569. Panel adapted
with permission from Hanley et al. [67]. b Bar graph of 6.9 year risk
of CVD in 3,606 participants with the metabolic syndrome (MS) and
with individual components of the metabolic syndrome, i.e. dyslipi-
daemia (Dyslip), hypertension (HTN), obesity (OB) and insulin
resistance (IR, highest HOMA quartile) in the Botnia Study. Panel
adapted with permission from Isomaa et al. [68]
Fig. 1 Insulin-stimulated glucose disposal (40 mU m
−2 min
−1,
euglycaemic–hyperinsulaemic clamp) in lean healthy control (CON)
participants, obese normal-glucose-tolerant participants (NGT), lean
drug-naive type 2 diabetic participants (T2DM), lean normal-glucose-
tolerant hypertensive participants (HTN), NGT hypertriacylglycero-
laemic (Hypertriacyl) participants and non-diabetic participants with
coronary artery disease (CAD). White sections, non-oxidative glucose
disposal (glycogen synthesis); black sections, glucose oxidation. **p
<0.01 vs CON; ***p<0.001 vs CON. Figure adapted with permission
from Kashyap et al. [19] and DeFronzo et al. [20]. To change glucose
uptake into SI units, divide by 180
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glucose utilisation, but causes hypertension and accelerated
atherosclerosis.
Insulin is a potent growth factor [20, 26, 27, 91, 92],
whose growth-promoting effects are mediated via the
mitogen-activated protein (MAP) kinase pathway [93].
After the interaction between IRS-1 and SHC, extracellular
regulated kinase (ERK) is activated [77, 94], translocates
into the nucleus and catalyses phosphorylation of transcrip-
tion factors that promote cell growth, cell proliferation and
cell differentiation [77]. Thus, this pathway plays an
important role in atherogenesis. MAP kinase blockade
prevents stimulation of insulin’s growth-promoting
effects, but has no effect on the metabolic actions of
insulin [95, 96]. Insulin resistance in the PI-3 kinase
(metabolic) pathway with intact MAP kinase signalling
activates multiple inflammatory pathways, including
inhibitor kβ (IkB)/nuclear factor kβ (NFkB) [97]a n d
c-Jun N-terminal kinase [98], which also cause insulin
resistance. Not surprisingly, sustained physiological
hyperinsulinaemia activates multiple genes involved in
inflammation [27].
Insulin receptor defects in type 2 diabetes Some studies
[44, 78, 99] have demonstrated decreased insulin binding to
monocytes and adipocytes in type 2 diabetic patients.
However, in muscle and liver, insulin binding to solubilised
insulin receptors is normal in obese normal glucose-tolerant
and lean type 2 diabetic participants [100].
Insulin receptor tyrosine kinase activity In normal-weight
and obese diabetic patients, insulin-stimulated insulin
receptor tyrosine kinase activity was reduced and could
not be explained by decreased insulin receptor number/
binding [101]. Normalisation of fasting plasma glucose
with weight loss corrected the defect in insulin receptor
tyrosine kinase [102], indicating that the defect is
acquired.
Fig. 4 a Insulin signal transduction system in individuals with normal
glucose tolerance (see text for a detailed discussion). NOS, nitric
oxide synthase. b In type 2 diabetic participants insulin signalling is
impaired at the level of IRS-1 leading to decreased glucose transport/
phosphorylation/metabolism and impaired nitric oxide synthase
activation/endothelial function. At the same time, insulin signalling
through the MAP kinase pathway is normally sensitive to insulin. The
compensatory hyperinsulinaemia (due to insulin resistance in the IRS-
1/PI-3 kinase pathway) results in excessive stimulation of this
pathway, which is involved in inflammation, cell proliferation and
atherogenesis (see text for a detailed discussion). SHC, Src homology
collagen. Reproduced from DeFronzo [1]
Fig. 3 a Predictive value (%) of CVD using the Framingham risk
engine in Framingham Heart Study (FHS), the Atherosclerosis Risk in
Community Study (ARIC), the Honolulu Heart Program (HHP), the
Puerto Rico Heart Health Program (PR), the Strong Heart Study
(SHS) and the Cardiovascular Health Study (CHS). On mean, the
Framingham Risk engine predicts only 69% of the risk of a future
cardiovascular event. Panel adapted with permission from D’Agostino
et al. [74]. b Excess carotid intima–media thickness (IMT) in relation
to the individual components of the insulin resistance (metabolic)
syndrome as listed. Amer, American; HTN, hypertension; F, female;
M, male; TG, triacylglycerol; GLU, glucose. Fields in dotted lines,
unexplained risk (a 31%; b, 30%). Panel adapted with permission
from Goldsen et al. [76]
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indicated in Fig. 4b, we have shown that in skeletal muscle
of lean individuals with normal glucose tolerance, physio-
logical hyperinsulinaemia increases insulin receptor and
IRS-1 tyrosine phosphorylation by 150% to 200% [94,
103]. In obese non-diabetic participants, activation of these
two insulin signalling events in muscle was reduced, while
in type 2 diabetic individuals insulin had no significant
stimulatory effect [94]. Association of PI-3 kinase with
IRS-1/IRS-2 was greatly reduced in obese non-diabetic and
type 2 diabetic participants and correlated closely with
impaired muscle glycogen synthase activity and with in
vivo insulin-stimulated glucose disposal [94].
MAP kinase signalling Our studies in human skeletal
muscle [94] (Fig. 4b) were the first to demonstrate that in
insulin-resistant type 2 diabetic and obese non-diabetic
individuals the profound insulin resistance in the PI-3
kinase pathway contrasts with the normal stimulatory effect
of insulin on the MAP kinase pathway (MAP kinase kinase
1 activity and ERK1/2 phosphorylation/activity) [94].
Maintained insulin stimulation of the MAP kinase pathway,
with persistent insulin resistance in the PI-3 kinase
pathway, represents an important pathogenic mechanism
for development of CVD in insulin-resistant states (see
subsequent discussion).
Molecular link between insulin resistance
and atherosclerosis
Our studies in man demonstrated that impaired IRS-1
tyrosine phosphorylation/PI-3 kinase activation in lean type
2 diabetic and obese non-diabetic participants causes a
profound defect in glucose transport/phosphorylation
and glycogen synthesis (Fig. 4b)[ 104, 105]. Because
nitric oxide synthase is activated by the same PI-3 kinase
pathway, nitric oxide production is impaired [106, 107],
resulting in endothelial dysfunction [108–110]a n d
accelerated atherosclerosis [110–113]. This pathogenic
sequence establishes the molecular basis linking insulin
resistance, inflammation and accelerated atherosclerosis
in people with type 2 diabetes mellitus and may help
account for the missing 30% CVD risk that cannot be
explained by circulating cardiovascular risk factors [74,
76]( F i g .4b). This pathogenic sequence also explains
why insulin resistance is a strong predictor of CVD
[67–73].
Once the insulin signalling defect becomes established, it
initiates a reverberating negative feedback cycle. Impaired
glucose utilisation causes hyperglycaemia, which stimulates
insulin secretion (Fig. 4b). Because the IRS-1/PI-3 kinase
pathway is defective, the MAP kinase pathway is
excessively stimulated since it is normally sensitive to
insulin. Increased IRS-1 serine phosphorylation, induced
by metabolic/inflammatory abnormalities present in the
diabetic state (reviewed by Draznin [114]), further impairs
insulin signalling through the PI-3 kinase pathway [115,
116]. In diabetic and obese patients, continued MAP
kinase pathway stimulation [94] causes vascular smooth
muscle proliferation, increased collagen formation and
excessive production of growth factors/inflammatory
cytokines, contributing to accelerated atherosclerosis.
Thesameinsulinsignallingdefectsthatwehavedemonstrated
in skeletal muscle of type 2 diabetic patients have been
demonstrated in arterial vascular smooth muscle cells
(VSMC) in animal models of diabetes and in humans [92,
117, 118].
Drazninandcolleagues[93, 114]h a v ep r o v i d e da d d i t i o n a l
evidence for this ‘dual insulin signalling hypothesis’.I n
cultured VSMCs and endothelial cells treated with PI-3
kinase inhibitors, insulin cannot activate nitric oxide
synthase to generate nitric oxide and these cells are no
longer protected from the detrimental effects of vascular
endothelial growth factor, platelet-derived growth factor
(PDGF) and other inflammatory peptides. Insulin con-
tinues to stimulate VSMC proliferation/migration even
though the PI-3 kinase pathway has been inhibited and
increases prenylated Ras (rat sarcoma) and Rho (Ras
related homologue), leading to augmented VSMC response
to the growth-promoting effects of IGF-1, epidermal
growth factor, PDGF and angiotensin II. These effects
are enhanced when PI-3 kinase is inhibited [119, 120].
The sensitising effect of VSMCs to angiotensin II is of
particular importance, since hyperinsulinaemia doubles the
ability of angiotensin II to transactivate NF-kB [120], a
powerful nuclear transcription factor that activates multi-
ple inflammatory pathways involved in atherogenesis
[121, 122] and causes IRS-1 serine phosphorylation,
which inhibits insulin signalling [123]. Angiotensin II also
serine phosphorylates IRS-1 in aortic smooth muscle and
skeletalmusclecells[124]. Thisprovidesapathophysiological
link between insulin resistance, atherogenesis and essential
hypertension.
Genetic vs acquired defects in insulin signal
transduction
To examine whether the insulin signalling defect is genetic
or acquired, we studied lean normal glucose-tolerant
offspring of two diabetic parents [65]. These offspring are
severely insulin-resistant [65, 103] and at high risk of
developing diabetes. Insulin-stimulated glucose disposal
was markedly reduced despite increased insulin receptor
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stimulated IRS-1 tyrosine phosphorylation/PI-3 kinase
activity were markedly reduced. From these observations
five points ensue: (1) early in the natural history of type 2
diabetes insulin receptor activation is normal (Fig. 4b); (2)
the rate-limiting step for insulin signalling resides at IRS-1;
(3) molecular abnormalities responsible for insulin resis-
tance are present long before onset of overt diabetes or
impaired glucose tolerance; (4) insulin normally augments
MAP kinase, but not PI-3 kinase, demonstrating dissocia-
tion between regulation of PI-3 kinase and MAP kinase
pathways; and (5) tissues of offspring with normal glucose
tolerance are being ‘incubated’ in a ‘sea’ of molecular
insulin resistance and atherogenicity from an early age,
explaining in part why clinically evident CVD is present in
15 to 20% of individuals at initial diagnosis [125] and why
insulin resistance and CVD are closely linked [19, 20, 44,
67–72]. Only thiazolidinediones simultaneously augment the
PI-3 kinase (metabolic) pathway while inhibiting the MAP
kinase (atherogenic) pathway [126, 127]. Thiazolidinediones
also enhance nitric oxide synthase activity, increasing nitric
oxide production [128–130]; they also reduce high-
sensitivity C-reactive protein levels and improve multiple
cardiovascular risk factors in type 2 diabetic participants
[131].
Lipotoxicity, insulin resistance and atherosclerotic CVD
The term ‘lipotoxicity’ was coined by Unger to describe
the deleterious effect of tissue fat accumulation on
glucose metabolism [132]. However, lipotoxicity has
assumed added significance (see textbox: Lipotoxicity).
Experimental NEFA elevation to reproduce levels in type
2 diabetes causes severe muscle/liver insulin resistance
[133–135] and inhibits insulin secretion [136], reproducing
the three basic core defects of type 2 diabetes. Elevated
plasma NEFA impair glucose oxidation/glycogen synthesis
[133] and decrease glucose transport/phosphorylation [104,
135]. Most importantly, lipid infusion to increase plasma
NEFA levels in participants with normal glucose tolerance
caused a dose–response inhibition of insulin receptor/IRS-1
tyrosine phosphorylation and PI-kinase activity, which
correlate closely with reduced insulin-stimulated glucose
disposal [137].
Magnetic resonance spectroscopic studies have demon-
strated that intramyocellular and intrahepatic fat accumulation
are closely associated with organ-specific insulin resistance
[138–141]. Intracellular toxic metabolites of triacylglycerol
and NEFA metabolism (fatty acyl CoA, diacylglycerol,
ceramides) cause severe insulin resistance by impairing
insulin signalling and multiple intracellular steps of glucose
metabolism [133, 137, 142]. To examine the causality of this
association, we treated type 2 diabetic patients with
acipimox, an inhibitor of lipolysis. The decline in plasma
NEFA (563 to 230 mmol/l) was associated with decreased
muscle long-chain fatty acyl CoA [143], which correlated
closely with enhanced insulin-stimulated muscle glucose
uptake (Fig. 5). The deleterious effect of increased intracel-
lular fat on insulin sensitivity is supported by the work of
Kim et al. [144], who overexpressed lipoprotein lipase in
muscle or liver in mice. In muscle this caused a marked
increase in fat content, severe insulin resistance and impaired
PI-3 kinase activity, without affecting hepatic insulin
sensitivity. Lipoprotein lipase overexpression in liver in-
creased hepatic fat content, induced severe hepatic insulin
resistance and impaired hepatic insulin signalling, but had no
effect on muscle [144]. Long-chain fatty acyl CoAs cause
IRS-1 serine phosphorylation, thereby inhibiting the PI 3
kinase pathway [145, 146].
In animals [147] and humans [148], plasma NEFA
elevation by lipid infusion also increased intramyocellular
diacylglycerol, a potent activator of protein kinase C (PKC)
isoforms, which inhibit insulin signalling through serine
phosphorylation of IRS-1 [149]. Muscle [150] and plasma
[151] ceramide levels are also increased in obese and type 2
diabetic individuals, correlating closely with severity of
insulin resistance.
In summary, much evidence supports the notion that
increased plasma NEFA/intramyocellular levels of toxic
lipid metabolites (long-chain fatty acyl CoAs, diacylgly-
cerol, ceramides) play a role in the pathogenesis of muscle/
liver insulin resistance.
NEFA, inflammation and atherosclerosis: the neglected
lipid
Type 2 diabetes and obesity are characterised by low-grade,
chronic inflammation [152–154], which could contribute to
Lipotoxicity  Reversal of lipotoxicity with thiazolidinediones 
￿  Elevated plasma NEFA  ￿  Decreases plasma NEFA 
￿  Increased tissue fat content  ￿  Decreases muscle long-chain fatty acyl CoA 
￿  Altered fat topography  ￿ Redistributes  fat 
￿  Adiposopathy  ￿ Reverses  adiposopathy 
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provides a molecular mechanism responsible for inflamma-
tion and insulin resistance in type 2 diabetes mellitus [91,
148, 152, 155]. Under basal conditions, NFkB is associated
with IkB in the cytoplasm (Fig. 6). Upon activation by
inflammatory factors, including fatty acyl CoAs, IkB kinase
phosphorylates IkB, causing IkB polyubiquitination and
degradation. The free NFkB translocates to the nucleus,
where it binds to target genes, stimulating inflammatory
mediators (TNFα, IL-1B, IL-6, PKC) involved in athero-
genesis [152, 156, 157]. TNFα, IL-6 and PKC, as well as IK
kinase, cause serine phosphorylation of IRS-1, inhibiting
insulin signalling and causing insulin resistance [123, 158].
Skeletal muscle IkB content is decreased in type 2
diabetic patients [159], indicative of increased NFkB
activity. We have confirmed this by demonstrating increased
NF-kB p50–p65 DNA binding activity in type 2 diabetic and
obese individuals (P Tantiwong, K Shammugasumdaran, A
Monroy, S Ghosh, E Cersosimo, A Sriwijitkamol, RA
DeFronzo, S Mohan, N Musi, unpublished results).
Reduced IkB and increased NFkB p50–p65 binding
activity were strongly correlated with reduced insulin
sensitivity.
Multiple stimuli [152], including lipids, activate IkB
kinase/NFkB, causing insulin resistance in cultured myo-
cytes [160] and muscle from rodents [155, 161]a n d
humans [162]. In human myocytes, palmitate enhances
NFkB activity and increases IL6 mRNA, a downstream
gene regulated by NFkB. Transfection of myocytes with an
adenovirus-IkB super repressor mutant blocked the aug-
mentation of NFkB activity and of IL6 mRNA expression
by palmitate [162].
Circulating NEFA also cause inflammation and insulin
resistance by directly activating plasma membrane recep-
tors, such as toll-like receptor 4 [162] (Fig. 7). In muscle of
obese and type 2 diabetic individuals, toll-like receptor 4
mRNA/protein content is increased and correlates closely
with HOMA-IR [162] and IkB/NFkB activation, providing
another pathway via which NEFA incite inflammation and
promote atherogenesis.
NEFA also stimulate formation of collagen, an integral
component of the atherosclerotic plaque [163, 164].
Physiological NEFA elevation in participants with normal
glucose tolerance increases mRNA expression of collagen,
fibronectin and lumican, as well as connective tissue
growth factor [134], a member of the CCN gene family,
which mediates fibrotic responses [163]. Increased connec-
tive tissue growth factor levels are a characteristic finding
in complicated atherosclerotic plaques and induce mono-
nuclear cell chemotaxis [164].
Plasma NEFA exert profound effects on endothelial
function. Insulin-stimulated blood flow is mediated via
nitric oxide [86] and is impaired in obese and type 2
diabetic individuals [108, 165]. Experimental plasma NEFA
elevation in participants with normal glucose tolerance
reduced endothelium-dependent blood flow, without alter-
ing endothelium-independent blood flow [166]. Endothelial
dysfunction is associated with accelerated atherosclerosis
and insulin resistance [110, 111], providing another
mechanism via which NEFA promote CVD in type 2
diabetes mellitus.
Adiposopathy
‘Adiposopathy’ is another form of lipotoxicity [131]. Fat
cells produce adipocytokines, which travel to distant sites
(muscle, liver, arterial tissue) where they exert deleterious
Fig. 5 a Intramyocellular lipid content (measured by magnetic
resonance spectroscopy) and (b) muscle long-chain fatty acyl CoA
(LC-FACoA) content in control (CON) and type 2 diabetic (T2DM)
participants. **p<0.01 for T2DM vs CON. c Relationship between
the increment in insulin-stimulated rate of glucose disposal (Rd) and
decrement in muscle LC-FACoA content in type 2 diabetic partic-
ipants after treatment with acipimox. p<0.01; r=0.74. Figure adapted
with permission from Bajaj et al. [143]
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of obese and type 2 diabetic individuals is infiltrated by
mononuclear cells and is in a state of chronic inflammation
[167]. The adipocytes and infiltrated macrophages secrete
proinflammatory/prothrombotic cytokines (TNFα, resistin,
IL-6, plasminogen activator inhibitor-1, angiotensinogen)
that promote atherogenesis and cause insulin resistance
(reviewed by Bays et al. [131]). Adipocytes also under-
produce adiponectin, a potent insulin-sensitising, anti-
atherogenic cytokine [131].
Fat topography
Accumulation of fat within the intraabdominal cavity, i.e.
visceral fat (Fig. 8), is associated with insulin resistance and
CVD [131, 168, 169]. Although the mechanism(s) for this
association remain(s) unclear, visceral obesity is part of the
insulin resistance (metabolic) syndrome [38–40]; however,
the individual components of the insulin resistance syn-
drome, not the increase in visceral fat, may account for the
increased incidence of CVD.
Fig. 7 Schematic representation of the toll-like receptor 4 (TLR-4)
pathway and its activation by NEFA. Dissociation of NFkB from IkB
allows it to diffuse into the nucleus where it can turn on genes
associated with inflammation, atherosclerosis and insulin resistance
(see text for a detailed discussion). CD14, cluster of differentiation 14;
IRAK, interleukin-1 receptor associated kinase, MD-2, myb regulated
gene; MYD88, myeloid differentiation primary response gene; TRAF,
TNFa receptor associated factor
Fig. 6 Relationship between in-
tracellular fatty acyl CoA levels,
IkB/NFkB and the insulin signal
transduction pathway (see text
for a detailed discussion). iNOS,
inducible nitric oxide synthase
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Tissue fat overload is explained by: (1) excessive energy
intake; (2) increased lipolysis in insulin-resistant adipo-
cytes, leading to increased plasma NEFA and enhanced
influx into muscle/liver; and (3) decreased fat oxidation.
Weight loss (energy-intake restriction) has proven effective
in reducing total body fat content [170]. Glucagon-like
peptide-1 analogues are potent appetite suppressants and
effectively promote weight loss [171].
Thiazolidinediones exert the following unique actions
that ameliorate lipotoxicity (Textbox 3): (1) decrease
plasma NEFA by inhibition of lipolysis; (2) reduction of
muscle long-chain fatty acyl CoA levels; (3) redistribu-
tion of fat within the body; and (4) amelioration of
adiposopathy.
Thiazolidinediones, insulin sensitivity and NEFA metabo-
lism Thiazolidinediones are potent insulin sensitisers in
muscle and liver [126, 127, 140, 141, 172, 173] and
improve sensitivity to the antilipolytic effect of insulin,
decreasing basal NEFA turnover/plasma NEFA [172].
Thiazolidinediones also improve hepatic insulin sensitivity,
leading to decreased basal hepatic glucose production and
enhanced hepatic glucose production suppression by insulin
[140, 172–174]. Reduced plasma NEFA levels correlate
closely with improved insulin-stimulated muscle glucose
disposal and decreased hepatic glucose production.
In type 2 diabetic patients, impaired insulin-stimulated
IRS-1 tyrosine phosphorylation and PI 3 kinase activity
[94] (Fig. 9) are improved by rosiglitazone [126], with
enhanced insulin signalling correlating closely with reduced
plasma NEFA. Similarly, pioglitazone increases insulin-
stimulated glucose disposal by 35% in association with
reduced fasting NEFA, muscle fat content and fatty acyl
CoAs [127, 173] (Fig. 5). These results provide strong
evidence that thiazolidinediones improve muscle insulin
sensitivity via reversal of lipotoxicity.
Mitochondrial dysfunction, lipotoxicity and thiazolidinedio-
nes Impaired ATP synthesis and mitochondrial dysfunction
have been demonstrated in insulin-resistant states including
ageing, offspring of diabetic parents, obesity and type 2
diabetes mellitus [175–179]. Using
31P nuclear magnetic
resonance spectroscopy, Petersen et al. [176] have shown
that decreased ATP synthesis is associated with increased
intramyocellular fat. In isolated mitochondria from obese
and type 2 diabetic individuals, we have demonstrated that
ATP synthesis is reduced [179, 180] and correlates closely
with decreased insulin-stimulated glucose disposal and
increased fasting plasma NEFA. To examine whether fatty
acid metabolites directly inhibit mitochondrial function, we
incubated mitochondria from participants with normal
glucose tolerance with palmitoyl carnitine [181]. At con-
centrations <2 μmol/l, palmitoyl carnitine stimulated ATP
Fig. 8 Fat topography in type 2 diabetes and effect of thiazolidine-diones
(TZD) (see text for a detailed discussion)
Fig. 9 Rosiglitazone (ROSI) treatment of type 2 diabetic patients
(T2DM) for 4 months markedly augmented insulin signalling through
the IRS-1/PI-3 kinase pathway without altering (a) insulin receptor
tyrosine phosphorylation, (b) IRS-1 tyrosine phosphorylation, (c)
association of p85 subunit of PI-3 kinase with IRS-1 and (d)
association of PI-3 kinase with IRS-1. *p<0.05; **p<0.01. Figure
adapted with permission from Miyazaki et al. [126]
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ly decreased ATP synthesis and inner mitochondrial
membrane potential, which provides the voltage gradient
driving electron transport.
Type 2 diabetic individuals and insulin-resistant offspring
with normal glucose tolerance have reduced expression of
multiple nuclear genes that encode enzymes involved in
oxidative metabolism, including peroxisome proliferator-
activated receptor (PPAR)γ coactivator (PGC-1) [182], the
master regulator of mitochondrial biogenesis [183]. A
twofold increase of plasma NEFA in participants with
normal glucose tolerance reduced muscle expression of
PGC-1 and multiple mitochondrial genes to levels observed
in diabetic individuals [134], providing evidence of ‘mito-
chondrial lipotoxicity’. Treatment of type 2 diabetic patients
with pioglitazone upregulated PGC-1α (also known as
PPARGC1A) and PGC-1β (also known as PPARGC1b)
mRNA expression in association with increased expression
of pyruvate dehydrogenase alpha 1 (PHDA1) and other
mitochondrial oxidative phosphorylation genes [175]
(Fig. 10), ameliorating ‘mitochondrial lipotoxicity’.
Pioglitazone also ameliorates lipotoxicity via effects
mediated through adiponectin and adiponectin receptor
(Fig. 11). Hypoadiponectinaemia is characteristic of type 2
diabetes. Thiazolidinediones increase plasma adiponectin
levels to or above those in non-diabetic patients [131, 173].
Adiponectin is a potent insulin sensitiser in muscle and
liver [184] and exerts multiple anti-atherogenic effects
[185, 186]. In type 2 diabetic patients and insulin-resistant
offspring with normal glucose tolerance, adiponectin
receptor 1 and 2 expression is reduced [187]. Pioglitazone
treatment increases expression of muscle adiponectin
receptors 1 and 2 and AMP kinase [188]. Similar effects
have been demonstrated in cultured human myocytes and
do not require PPARγ stimulation [188]. Pioglitazone also
upregulated acetyl-CoA carboxylase and carnitine palmi-
toyl transferase expression/activity, leading to the postulate
(Fig. 11) that pioglitazone increases plasma adiponectin
levels and expression of adiponectin receptors 1 and 2,
stimulating AMP kinase and acetyl-CoA carboxylase
activity, with resultant inhibition of malonyl CoA. This
augments carnitine palmityol transferase I activity and
enhances NEFA flux into mitochondria, where they
undergo beta oxidation. The result is a decrease in
intramyocellular fatty acyl CoA levels, leading to improved
muscle insulin signalling/insulin sensitivity.
Thiazolidinediones and fat topography: clinical implica-
tions Thiazolidinediones redistribute body fat by reducing
visceral and increasing subcutaneous fat [189, 190] (Fig. 8).
They also reduce muscle fatty acyl CoA, leading to
improved insulin sensitivity and glycaemic control [126,
127, 140, 141, 172, 173, 176]. Thiazolidinediones also
reduce liver fat and are effective in treating non-alcoholic
steatohepatitis [139, 191]. In a randomised, placebo
controlled study of 55 participants with type 2 diabetes/
impaired glucose tolerance and biopsy-proven non-
alcoholic steatohepatitis, pioglitazone reduced liver fat by
Fig. 10 PGC-1α and PGC-1β expression in muscle of (a, b)
individuals with normal-glucose-tolerance and without family history
(FH−) of diabetes, insulin-resistant normal-glucose-tolerant offspring
of two type 2 diabetic parents (FH+) and participants with type 2
diabetes mellitus (T2DM). c A strong linear relationship exists
between PGC-1α mRNA and PDHA1 mRNA, and the expression of
other mitochondrial genes (not shown) involved in oxidative phos-
phorylation. White diamonds, FH−; black triangles, type 2 diabetes
mellitus; hatched squares, FH+. d, e Pioglitazone (PIO) treatment of
type 2 diabetic patients significantly increased the expression of PGC-
1α and PGC-1β mRNA in muscle. *p<0.05 for FH+vs FH−;* * p<
0.01 for FH+ and T2DM vs FH−, and (d, e)* p<0.05 for PIO vs
Basal. Figure adapted with permission from Patti et al. [182] and
Coletta et al. [175]
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aspartate aminotransferase, and reduced hepatic inflamma-
tion, ballooning necrosis and fibrosis [139].
Thiazolidinediones preserve beta cell function in type 2
diabetic patients [192]. Eight double-blind, placebo/active
comparator-controlled studies demonstrate that thiazolidi-
nediones have a durable effect in reducing HbA1c
( r e v i e w e db yD e F r o n z o[ 1]) because of a beta cell
protective effect. Five studies in participants with impaired
glucose tolerance document that thiazolidinediones mark-
edly reduced conversion to type 2 diabetes, primarily by
improving beta cell function (reviewed by DeFronzo [1]).
Using the gold standard insulin secretion/insulin resis-
tance (disposition) index, both pioglitazone and rosiglita-
zone have been shown to improve beta cell function in
drug naive and sulfonylurea-treated type 2 diabetic
patients [192]. Thiazolidinediones augment beta cell
function by multiple mechanisms, including direct effects
(increased GLUT2, glucokinase, Pdx)e x e r t e dt h r o u g h
PPARγ [193], and by reducing intracellular fatty acyl
CoA levels [194–196].
Myocardial lipid content is increased in type 2 diabetic
individuals[197, 198] andcontributestodiastolicdysfunction
[198, 199]. The myocardium in type 2 diabetes is markedly
insulin-resistant [61, 198]. The insulin resistance cannot be
explained by coronary artery disease [199] and correlates
with increased myocardial fat [198, 200]. Rosiglitazone
similarly improved myocardial and skeletal muscle insulin
resistance [62]. Although myocardial fat content was not
measured in these studies, it is reasonable to hypothesise that
thiazolidinediones exert their myocardial insulin sensitising
effect, in part by reducing myocardial fat content.
Coronary and carotid arterial disease represent the major
cause of mortality in patients with type 2 diabetes [4].
Elevated plasma LDL-cholesterol and triacylglycerol, and
reduced HDL-cholesterol all contribute to accelerated athero-
genesis in type 2 diabetes. Quantitative lipid analysis of
atherosclerotic plaques reveals large amounts of NEFA and
fatty acid metabolites [35–37], which can stimulate inflam-
matory pathways involved in atherogenesis. Pioglitazone
reduces plasma triacylglycerol, increases HDL-cholesterol,
converts small dense LDL particles to larger more buoyant
ones and decreases apolipoprotein B-100 without altering
plasma LDL-cholesterol [201, 202]. Thiazolidinediones also
markedly reduce plasma NEFA [127, 139, 172], which
would be expected to reduce fatty acyl CoAs and other toxic
fatty acid metabolites within arterial smooth muscle cells,
thus inhibiting atherogenesis. Thiazolidinediones also inhibit
release of proinflammatory, prothrombotic, atherogenic
adipocytokines from fat tissue [139, 141, 172, 203]a n d
redistribute fat from visceral (atherosclerotic equivalent) to
subcutaneous depots [189, 190]. Thus, thiazolidinediones
ameliorate all components of the ‘lipotoxicity syndrome’.
Therefore, one could expect thiazolidinediones to reduce
cardiovascular events in type 2 diabetes.
The Prospective Pioglitazone Clinical Trial in Macro-
vascular Events [204] examined the effect of pioglitazone
on cardiovascular outcomes in type 2 diabetes patients with
a previous cardiovascular event. Although the primary
composite endpoint did not reach statistical significance, a
Fig. 11 Amelioration of lipo-
toxicity by action of pioglita-
zone in increasing the plasma
adiponectin concentration and
levels of adiponectin receptors
(ADIPOR) 1 and 2. See text for
a detailed discussion. ACC,
acetyl CoA carboxylase; CPT-1,
carnitine palmitoyl transferase-
1; CREB, cAMP response
element binding; DAG, diacyl-
glycerol; MEF2C, myocyte en-
hancer factor 2C. Figure adapted
with permission from Civitarese
et al. [187] and Coletta et al.
[175]
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principal endpoint (time to death, myocardial infarction,
stroke) was significantly reduced. Analysis of all double-
blind placebo-controlled pioglitazone trials in the USA
demonstrated a significant reduction in cardiovascular
events [205]. Consistent with these trials, pioglitazone
decreased carotid intima medial thickness [206]a n d
coronary atherosclerotic plaque volume [207].
Weight gain and thiazolidinedione paradox Thiazolidine-
dione treatment is associated with modest weight gain (1–
3 kg) that occurs within the first 12 months of treatment.
Paradoxically, the greater the weight gain, the greater the
reduction in HbA1c and the greater the improvements in
insulin sensitivity and beta cell function [173, 189, 192].
This paradox is explained as follows. Thiazolidinediones
mobilise fat from muscle, liver and beta cells leading to
improved insulin sensitivity and beta cell function. PPARγ
receptors are abundant in hypothalamic appetite regulation
centres [208]. Thus, thiazolidinediones simultaneously
evoke two effects: (1) PPARγ activation in muscle/liver/
adipocytes/beta cells; and (2) stimulation of appetite. The
former improves glucose homeostasis, while the latter
promotes weight gain. Consequently, increased body
weight is a strong predictor of improved glycaemic control
(HbA1c) in type 2 diabetes mellitus [204].
Summary
Insulin resistance in the PI-3 kinase pathway with normal
insulin sensitivity in the MAP kinase pathway plays an
important role in accelerated atherogenesis in patients with
type 2 diabetes mellitus. Lipotoxicity is a major cause of
insulin resistance and impaired beta cell function in type 2
diabetes mellitus and plays a central role in the accelerated
CVD. Interventions that mobilise fat out of tissues
(restriction of energy intake, thiazolidinediones, glucagon-
like peptide-1 analogues) are likely to produce a durable
reduction in glycaemia and reduce atherosclerotic cardio-
vascular events.
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